These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

873 related items for PubMed ID: 24378408

  • 1. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [Abstract] [Full Text] [Related]

  • 2. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C, Menan D, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Simon R, Schlomm T, Steurer S, Krech T.
    BMC Cancer; 2015 Jul 23; 15():538. PubMed ID: 26202067
    [Abstract] [Full Text] [Related]

  • 3. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.
    Eur J Cancer; 2014 Mar 23; 50(4):852-61. PubMed ID: 24380696
    [Abstract] [Full Text] [Related]

  • 4. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.
    Int J Cancer; 2014 Sep 15; 135(6):1399-407. PubMed ID: 24510842
    [Abstract] [Full Text] [Related]

  • 5. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C, Kleinhans S, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Marx A, Sauter G, Wittmer C, Huland H, Simon R, Schlomm T, Steurer S.
    Int J Cancer; 2016 Mar 01; 138(5):1199-206. PubMed ID: 26383228
    [Abstract] [Full Text] [Related]

  • 6. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T.
    Oncol Rep; 2015 Sep 01; 34(3):1211-20. PubMed ID: 26134445
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
    Tsourlakis MC, Schoop M, Plass C, Huland H, Graefen M, Steuber T, Schlomm T, Simon R, Sauter G, Sirma H, Minner S.
    Hum Pathol; 2013 Sep 01; 44(9):1789-96. PubMed ID: 23642739
    [Abstract] [Full Text] [Related]

  • 8. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
    Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D, Tehrani AA, Simon R, Tennstedt P, Graefen M, Wittmer C, Brors B, Plass C, Korbel J, Weischenfeldt J, Sauter G, Huland H, Tsourlakis MC, Minner S, Schlomm T.
    Eur Urol; 2014 Dec 01; 66(6):978-81. PubMed ID: 25015038
    [Abstract] [Full Text] [Related]

  • 9. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
    Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.
    Am J Pathol; 2012 Aug 01; 181(2):401-12. PubMed ID: 22705054
    [Abstract] [Full Text] [Related]

  • 10. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
    Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A.
    Prostate; 2014 Jul 01; 74(10):1012-22. PubMed ID: 24789172
    [Abstract] [Full Text] [Related]

  • 11. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
    Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, Steurer S.
    Clin Cancer Res; 2015 Aug 01; 21(15):3471-9. PubMed ID: 25925890
    [Abstract] [Full Text] [Related]

  • 12. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S.
    Exp Mol Pathol; 2013 Oct 01; 95(2):227-34. PubMed ID: 23948277
    [Abstract] [Full Text] [Related]

  • 13. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F.
    Carcinogenesis; 2017 Dec 07; 38(12):1180-1187. PubMed ID: 29029032
    [Abstract] [Full Text] [Related]

  • 14. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W.
    Prostate; 2013 Nov 07; 73(15):1690-8. PubMed ID: 23843146
    [Abstract] [Full Text] [Related]

  • 15. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
    Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.
    Mod Pathol; 2014 Jan 07; 27(1):96-106. PubMed ID: 23887301
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A, Kylies D, Hube-Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Salomon G, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Krech T, Schlomm T, Melling N.
    Hum Pathol; 2016 Feb 07; 48():102-10. PubMed ID: 26614400
    [Abstract] [Full Text] [Related]

  • 18. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
    Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C.
    Prostate; 2019 Feb 07; 79(3):302-311. PubMed ID: 30430607
    [Abstract] [Full Text] [Related]

  • 19. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T.
    PLoS One; 2015 Feb 07; 10(6):e0128525. PubMed ID: 26030748
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N, Thomsen E, Tsourlakis MC, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S, Krech T.
    Carcinogenesis; 2015 Nov 07; 36(11):1333-40. PubMed ID: 26392259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.